Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
57,464,862
-
Shares change
-
-519,811
-
Total reported value, excl. options
-
$1,317,641,644
-
Value change
-
+$12,220,647
-
Put/Call ratio
-
16.69%
-
Number of buys
-
65
-
Number of sells
-
-77
-
Price
-
$22.93
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2023
177 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2023.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57,464,862 shares
of 62,162,717 outstanding shares and own 92.44% of the company stock.
Largest 10 shareholders include BVF INC/IL (5,744,848 shares), FARALLON CAPITAL MANAGEMENT LLC (5,734,430 shares), BlackRock Inc. (5,543,902 shares), RTW INVESTMENTS, LP (5,315,514 shares), VANGUARD GROUP INC (3,153,916 shares), STATE STREET CORP (2,729,929 shares), Point72 Asset Management, L.P. (2,613,453 shares), JOHNSON & JOHNSON (2,449,183 shares), Kynam Capital Management, LP (2,004,875 shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1,291,701 shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.